COGT

Quote

Short

News

Articles

Message Board

Cogent Biosciences Inc. (NASDAQ : COGT ) News

News Releases

COGT News Releases

June 30, 2026 08:00:00 am

GlobeNewswire

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

June 24, 2026 09:45:42 am

SeekingAlpha

10 mid-cap U.S. healthcare stocks with the strongest momentum grades

June 14, 2026 09:13:38 am

SeekingAlpha

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage

June 12, 2026 08:01:00 am

GlobeNewswire

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

June 12, 2026 08:00:00 am

GlobeNewswire

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

June 02, 2026 10:10:32 am

SeekingAlpha

These 10 mid-cap U.S. healthcare companies carry the market's most expensive valuations

June 01, 2026 09:24:44 am

24/7 Market News

Lilly's Phase 3 Breakthrough Ignites Race for the Next Cancer Stock Breakout

May 30, 2026 08:00:00 am

GlobeNewswire

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

May 28, 2026 09:12:57 am

SeekingAlpha

Cogent Bio granted FDA priority review for lead asset in tumor indication

May 28, 2026 08:00:00 am

GlobeNewswire

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account